Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

• Revvity’s new maternal and fetal biochemistry testing platform
• Designed for accessibility, simplicity, and flexibility
• Purpose-built for small to mid-sized labs and clinics to enable this capability in-house for the first time

Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.

The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes and hypertension. Despite international guidelines recommending screening, access has historically been limited to high-throughput centralized laboratories. SuperFlex addresses these gaps by delivering three core advantages:

• Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low
• Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle™ software for streamlined risk assessment and LIMS data transfer
• Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows

"This SuperFlex offering represents a significant addition to our prenatal portfolio," said Anna Godenhjelm, vice president and general manager of reproductive health at Revvity. "By removing the financial and operational barriers to in-house prenatal screening, we are giving more women access to potentially life-saving testing regardless of where they receive care."

The platform also includes a test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing.

The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260810996301/en/